GI CANCERS

The FDA approval of Guardant Shield marks the second blood-based diagnostic test for colorectal cancer in those age 45 and older at average risk of the disease.

A new dendritic cell vaccine has shown promising results in extending survival for pancreatic cancer patients by stimulating the immune system to fight tumor cells.

Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.

A dendritic cell vaccine called DOC1021 shows early promise in treating pancreatic cancer and has received a fast track designation from the FDA.

The ESOGUARD BE-1 trial demonstrated that the EsoGuard test, combined with EsoCheck, effectively detects esophageal precancer and supports its use as a screening tool to prevent esophageal cancer.

The FDA has received a 505(b)(2) new drug application seeking approval for a lutetium Lu 177 dotatate injection as a potential treatment for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

MRG004A, a novel antibody-drug conjugate, elicited antitumor activity and had manageable toxicities when used in heavily pretreated patients with multiple tumor types with high tissue factor.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.

Zolbetuximab could become the first CLDN18.2-targeted therapy approved for this patient population in the US.

VCN-01, an adenovirus therapy, received fast track designation from the FDA for treating metastatic pancreatic cancer in combination with standard chemotherapy.

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.

Using neoadjuvant atezolizumab followed by atezolizumab plus chemotherapy before surgery for gastric or gastroesophageal junction tumors appeared to be effective and warrants further study.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

A biologics license application for zanidatamab is being reviewed by the FDA for treating previously treated, HER2-positive biliary tract cancer.

During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.

A fast track designation from the FDA has been given to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.

Cambritaxestat, a first-in-class therapy in development for highly fibrotic cancer indications that overexpress autotaxin, has been granted an orphan drug designation from the FDA in pancreatic cancer.